Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NPX461
- Development stage
- Preclinical
- Lead developer
- Neurophoenix
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
NPX461 is an investigational cell-penetrating (CPM) fusion protein being developed by Neurophoenix for the treatment of optic neuropathies, specifically non-arteritic anterior ischemic optic neuropathy (NAION) and glaucoma. The drug utilizes a platform based on rabies virus glycoprotein biomimicry to deliver a therapeutic protein that disrupts the protein-protein interaction between Phosphatase and tensin homolog (PTEN) and the kinases MAST1 and MAST2. By inactivating PTEN, NPX461 aims to unlock the intrinsic regenerative capacity of neurons, providing both neuroprotective and neuroregenerative effects to promote the repair and survival of retinal ganglion cells. It is currently in the preclinical candidate stage.
02
Targets
MAST1 (Cytoplasmic linker associated protein 1)MAST2 (Microtubule-associated serine/threonine-protein kinase 2)PTEN (Phosphatase and tensin homolog deleted on chromosome ten)
Beyond the preview
Go deeper on NPX461.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NPX461.